Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M A Wallace

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Prostate Cancer and Prostatic Diseases|November 15, 2006
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-upM Wirth, C Tyrrell, K Delaere, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2005
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeM Wirth, C Tyrrell, K Delaere, et al.
British Journal of Cancer|July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epitheliumR G Keedwell, Y Zhao, L A Hammond, et al.
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Prostate Cancer and Prostatic Diseases|November 15, 2006
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-upM Wirth, C Tyrrell, K Delaere, et al.
Prostate Cancer and Prostatic Diseases|June 3, 2005
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeM Wirth, C Tyrrell, K Delaere, et al.
British Journal of Cancer|July 22, 2004
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epitheliumR G Keedwell, Y Zhao, L A Hammond, et al.
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
Pageof 2